Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. pharmacokinetic modeling physiology based pharmacokinetic
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Pharmacokinetic Modeling Physiology Based Pharmacokinetic Articles & Analysis

136 news found

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

Watertown, MA — November 25, 2024—In the spirit of Thanksgiving, Biopharma PEG Scientific Inc. would like to express its sincere gratitude to our esteemed customers and partners for their trust and support. It is a privilege to collaborate with you, and we look forward to further strengthening our partnership in the future.As a gesture of our appreciation, we are pleased to announce a 30% ...

ByBiopharma PEG Scientific Inc


Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

Protheragen-ING AI-Pharma’s AI-Powered Drug Discovery and Design Platform—A Paradigm Shift in Drug Development

In the ever-evolving landscape of pharmaceutical research and development, the demand for innovative and efficient drug discovery methods is more pressing than ever. At the forefront of this demanding field is Protheragen-ING AI-Pharma, a contract research and development biotechnology company, offering cutting-edge solutions to researchers through its AI-powered drug discovery and design ...

ByProtheragen-ING


CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...

ByCD Formulation


Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy

Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy

Watertown, MA — October 24, 2024 — Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical ...

ByBiopharma PEG Scientific Inc


Ace Therapeutics Unveils Model Development Services to Power Up Psychiatric Drug R&D

Ace Therapeutics Unveils Model Development Services to Power Up Psychiatric Drug R&D

Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development. Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively treat ...

ByAce Therapeutics


CD Formulation Offers Robust Expertise in Pharmacology to Aid Veterinary Drug Development

CD Formulation Offers Robust Expertise in Pharmacology to Aid Veterinary Drug Development

CD Formulation, an expert in the pharmaceutical research and development field, has announced the expansion of its comprehensive pharmacological services to support the burgeoning sector of veterinary drugs. The move is poised to elevate the standard and efficacy of veterinary pharmaceuticals, reinforcing CD Formulation’s dedication to the well-being of animals globally. “Our ...

ByCD Formulation


CD Formulation Enables Efficacy Evaluation of Oral Thin Films: Ensuring Therapeutic Efficacy and Safety

CD Formulation Enables Efficacy Evaluation of Oral Thin Films: Ensuring Therapeutic Efficacy and Safety

A breakthrough in CD formulation has enabled researchers to evaluate the efficacy of oral thin films, ensuring both therapeutic efficacy and safety. This new development has the potential to revolutionize the way oral medications are tested and administered, leading to more precise and effective treatments for a wide range of medical conditions. The development of oral thin films has gained ...

ByCD Formulation


Biopharma PEG Assists ADC Development with Monodispersed PEGs

Biopharma PEG Assists ADC Development with Monodispersed PEGs

Biopharma PEG, a leading name in the pharmaceutical industry, is proud to announce a groundbreaking advancement in the field of Antibody-Drug Conjugate (ADC) development. The company now offers monodispersed Polyethylene Glycols (PEGs) on a scale ranging from grams to kilograms, and even on a ton scale. Notable PEGs include mPEG36-NH2, NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA, and more.ADCs ...

ByBiopharma PEG Scientific Inc


Maximizing Therapeutic Potential: CD Formulation's Versatile Drug Delivery Systems Advance Pharmacokinetics and Pharmacodynamics   

Maximizing Therapeutic Potential: CD Formulation's Versatile Drug Delivery Systems Advance Pharmacokinetics and Pharmacodynamics  

In the ever-evolving field of pharmaceuticals, CD Formulation has emerged as a major player in developing innovative drug delivery systems aimed at enhancing the efficacy and safety of therapies. Through its expertise in various cutting-edge technologies such as microneedle and thin film technologies, transdermal patches, microencapsulation, and nanoparticle development, CD Formulation is ...

ByCD Formulation


Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

Creative BioMart, one of the world leading biotechnology companies serving science, recently updated its R-PEAPC Conjugated Proteins offerings to meet different research needs and applications. R-PE Labeled Proteins are labeled products generated by combining R-PE fluorescent dyes with proteins. R-PE labeled protein is non-toxic, odorless, and has high stability. And when the excitation ...

ByCreative BioMart


Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

Alfa Chemistry serves as an emerging pharmaceutical research organization with a mission to revolutionize the field of preclinical drug research with its wide range of comprehensive services. With a commitment to quality and excellence, Alfa Chemistry offers pharmacological analysis, drug safety evaluation, pharmacokinetic analysis, and bioanalytical services to streamline the drug development ...

ByAlfa Chemistry


BOC Sciences Introduces a Novel XDC Bioconjugation Platform to Advance Biomedical Research

BOC Sciences Introduces a Novel XDC Bioconjugation Platform to Advance Biomedical Research

BOC Sciences, a leading supplier of research chemicals and custom services, has unveiled its innovative XDC bioconjugation platform, providing a significant tool for drug delivery. The newly developed XDC bioconjugation platform offered by BOC Sciences introduces a range of advanced technologies and optimized protocols, revolutionizing the process of linking compounds to biomolecules. By ...

ByBOC Sciences


BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate

BOC Sciences Unveils Comprehensive Capabilities of Custom Peptide Drug Conjugate

BOC Sciences, a leading CRO in the USA, unveils its comprehensive capabilities for custom peptide drug conjugate from project design to commercial production. With its well-established conjugation platform, BOC Sciences supports pharmaceutical and biotechnology clients at the forefront of drug conjugation. Peptide-drug conjugates (PDCs) are mainly used in anti-cancer therapy, which integrates the ...

ByBOC Sciences


Araris Biotech appoints Bernd Schlereth as Chief Development Officer

Araris Biotech appoints Bernd Schlereth as Chief Development Officer

Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in pharmaceutical drug development. Between 2019 and 2021 Dr. Bernd Schlereth worked as Vice President Oncology Research at Molecular Partners AG. From 2013 to ...

ByAraris Biotech AG


MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that preliminary results from the ongoing Phase 1/2 study (NCT04104776) of tulmimetostat (CPI-0209) monotherapy in heavily pretreated patients with advanced cancers showed responses or disease stabilization in five cohorts with evaluable patients. Tulmimetostat is an oral, investigational next-generation selective dual inhibitor of EZH2 and ...

ByMorphoSys AG


Nanoparticulate Peptide Delivery Exclusively To The Brain Produces Tolerance Free Analgesia

Nanoparticulate Peptide Delivery Exclusively To The Brain Produces Tolerance Free Analgesia

There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...

ByVirpax Pharmaceuticals


Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial

Lipella Pharma Sees Positive Results for LP-10 Phase 2a Trial

Lipella Pharmaceuticals Inc. said it saw positive top-line results from its recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis. The biotechnology company said its next step will be to communicate with the Food and Drug Administration on the study’s results and the pathway forward to seeking regulatory approval ...

ByLipella Pharmaceuticals Inc.


Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

Starton Therapeutics’ STAR-LLD Continuous Delivery Shows Superior Tumor Reduction and Progression Free Survival (PFS) Compared to Pulsatile Lenalidomide Treatment in Lenalidomide-Resistant Model

Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. In this preclinical study: continuous delivery of lenalidomide resulted in improvements in the ...

ByStarton Therapeutics


Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

Oligomerix Presents Data from IND-Enabling Studies on Clinical Candidate at Clinical Trials on Alzheimer’s Disease (CTAD) and Neuroscience 2022 Meetings

Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings ...

ByOligomerix, Inc.


CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ?

Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...

ByAriana Pharma

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT